Congressmembers Langworthy, Schrier Introduce Bipartisan Bill to Lower Prescription Drug Costs by Expanding Access to Biosimilars
expected to conduct additional clinical studies even when existing evidence demonstrates the biosimilar is just as safe … before the FDA may approve a biosimilar when existing scientific evidence is sufficient. Preserve the FDA's authority